Financial reports
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
6 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K/A
2022 FY
Annual report (amended)
27 Apr 23
10-K
2022 FY
Annual report
20 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
3 Apr 24
8-K
Report of Independent Registered Public Accounting Firm
21 Mar 24
8-K
Regulation FD Disclosure
19 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
14 Mar 24
8-K
Graphite Bio Declares Special Dividend
8 Mar 24
8-K
Other Events
5 Mar 24
8-K
Other Events
26 Dec 23
8-K
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
15 Nov 23
8-K
Entry into a Material Definitive Agreement
30 Oct 23
8-K/A
Departure of Directors or Certain Officers
13 Sep 23
Registration and prospectus
Other
EFFECT
Notice of effectiveness
11 Apr 24
EFFECT
Notice of effectiveness
14 Feb 24
SEC STAFF
SEC staff action: Order
13 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
9 Feb 24
CORRESP
Correspondence with SEC
5 Feb 24
SEC STAFF
SEC staff action: Order
1 Feb 24
UPLOAD
Letter from SEC
1 Feb 24
CORRESP
Correspondence with SEC
17 Jan 24
Ownership
SC 13G/A
EcoR1 Capital, LLC
8 Apr 24
3
Initial statement of insider ownership
28 Mar 24
SC 13G
Alpha Wave Ventures GP, Ltd
28 Mar 24
SC 13D
RA CAPITAL MANAGEMENT, L.P.
28 Mar 24
4
Rajeev M. Shah
25 Mar 24
3
Rajeev M. Shah
25 Mar 24
4
Shelley B Thunen
25 Mar 24
SC 13G/A
Samsara BioCapital, L.P.
25 Mar 24
4
JAMES W MCCOLLUM
25 Mar 24
4
Frederic Guerard
25 Mar 24